European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme

M. J. van den Bent*, W. Grisold, D. Frappaz, R. Stupp, J. P. Desir, T. Lesimple, C. Dittrich, M. J A de Jonge, A. Brandes, M. Frenay, A. F. Carpentier, P. Chollet, J. Oliveira, B. Baron, D. Lacombe, M. Schuessler, P. Fumoleau

*Corresponding author for this work

Research output: Contribution to journalArticle

33 Scopus citations

Abstract

Background: Glufosfamide is a new alkylating agent in which the active metabolite of isophosphoramide mustard is covalently linked to β-D-glucose to target the glucose transporter system and increase intracellular uptake in tumor cells. We investigated this drug in a multicenter prospective phase II trial in recurrent glioblastoma multiforme (GBM). Patients and methods: Eligible patients had recurrent GBM following surgery, radiotherapy and no more than one prior line of chemotherapy. Patients were treated with glufosfamide 5000 mg/m2 administered as a 1-h intravenous infusion. Treatment success was defined as patients with either an objective response according to Macdonald's criteria or 6 months progression-free survival. Toxicity was assessed with the Common Toxicity Criteria (CTC) version 2.0. Results: Thirty-one eligible patients were included. Toxicity was modest, the main clinically relevant toxicities being leukopenia (CTC grade >3 in five patients) and hepatotoxicity (in three patients). No responses were observed; one patient (3%; 95% confidence interval 0 to 17%) was free from progression at 6 months. Pharmacokinetic analysis showed a 15% decrease in area under the curve and glufosfamide clearance in patients treated with enzyme-inducing antiepileptic drugs, but no effect of these drugs on maximum concentration and plasma half-life. Conclusion: Glufosfamide did not show significant clinical antitumor activity in patients with recurrent GBM.

Original languageEnglish (US)
Pages (from-to)1732-1734
Number of pages3
JournalAnnals of Oncology
Volume14
Issue number12
DOIs
StatePublished - Dec 2003

Keywords

  • Chemotherapy
  • Glioblastoma multiforme
  • Glufosfamide
  • Recurrent

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme'. Together they form a unique fingerprint.

  • Cite this

    van den Bent, M. J., Grisold, W., Frappaz, D., Stupp, R., Desir, J. P., Lesimple, T., Dittrich, C., de Jonge, M. J. A., Brandes, A., Frenay, M., Carpentier, A. F., Chollet, P., Oliveira, J., Baron, B., Lacombe, D., Schuessler, M., & Fumoleau, P. (2003). European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme. Annals of Oncology, 14(12), 1732-1734. https://doi.org/10.1093/annonc/mdg491